The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

ConclusionsBased on our results, we conclude that GSK458 may serve as an attractive candidate to treat ovarian cancer.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research